What is the global market size of MicroRNA Market?

MicroRNA Market size was valued at USD 1001.59 Million in 2021 and is poised to grow from USD 1173.86 Million in 2022 to USD 4178.66 Million by 2030, at a CAGR of 17.2% during the forecast period (2023-2030).

Who are the key vendors in the Global MicroRNA Market?

The global microRNA market is characterized by a highly competitive landscape, with numerous players striving to establish their presence and gain a competitive edge. The market is driven by intense research and development activities aimed at discovering novel microRNA biomarkers, therapeutic targets, and diagnostic tools. These advancements are fueling the development of innovative microRNA-based products and solutions, further intensifying the competition among market participants. Key players in the global microRNA market include biotechnology and pharmaceutical companies, academic and government research institutes, and contract research organizations. These entities contribute to the market by conducting extensive research, clinical trials, and commercialization of microRNA-based products. Furthermore, collaborations and partnerships between industry players and research institutions are common, allowing for knowledge sharing and synergistic advancements. Market participants strive to differentiate themselves by offering a wide range of microRNA-related products and services, including miRNA isolation kits, miRNA quantification assays, miRNA expression profiling arrays, miRNA functional analysis tools, and miRNA sequencing services. Additionally, companies focus on developing proprietary technologies and platforms that enhance the efficiency, accuracy, and sensitivity of microRNA analysis. To stay competitive, market players engage in strategic initiatives such as mergers and acquisitions, partnerships, and collaborations. These activities help them expand their product portfolios, strengthen their market presence, and access new geographical markets. Furthermore, companies invest in research and development to drive innovation and maintain a pipeline of cutting-edge microRNA-based products. The competitive landscape is also influenced by intellectual property rights and patent protection. Securing patents for novel microRNA-related discoveries and technologies is crucial for market players to safeguard their innovations and maintain a competitive advantage. 'Qiagen N.V. - Netherlands', 'Thermo Fisher Scientific Inc. - US', 'Agilent Technologies, Inc. - US', 'Illumina, Inc. - US', 'Merck KGaA - Germany', 'F. Hoffmann-La Roche Ltd. - Switzerland', 'Bio-Rad Laboratories, Inc. - US', 'PerkinElmer, Inc. - US', 'System Biosciences LLC - US', 'New England Biolabs, Inc. - US', 'NanoString Technologies, Inc. - US', 'Exiqon A/S - Denmark', 'Takara Bio Inc. - Japan', 'GenScript Biotech Corporation - US', 'Eurofins Scientific SE - Luxembourg', 'Novartis AG - Switzerland', 'Bio-Techne Corporation - US', 'Agios Pharmaceuticals, Inc. - US', 'Abcam plc - United Kingdom', 'Promega Corporation - US'.

What is the key driver of Global MicroRNA Market?

Technological advancements in genomics and molecular biology, such as next-generation sequencing and microarray platforms, have enabled high-throughput analysis of microRNAs. These technologies provide researchers with valuable tools to identify and characterize microRNAs, leading to increased research activities and driving market growth.

What is the key market trend for Global MicroRNA Market?

Growing Collaboration between Industry and Academia: Collaborations between biotechnology and pharmaceutical companies, academic research institutions, and government organizations are increasingly common in microRNA research. These collaborations leverage the expertise, resources, and knowledge of multiple stakeholders to accelerate the development and commercialization of microRNA-based products and solutions.

Which region accounted for the largest share in Global MicroRNA Market?

North America dominates the microRNA market due to the presence of a well-established healthcare infrastructure, significant investments in research and development, and a strong biotechnology and pharmaceutical industry. The region is home to several key market players and academic research institutes actively engaged in miRNA research. Additionally, favorable government initiatives, collaborations between academia and industry, and the availability of advanced technologies contribute to the dominance of North America in the microRNA market.

MicroRNA Market Size, Share, Growth Analysis, By Products & Services(Services [Type (Isolation & Purification, miRNA cDNA Synthesis, Profiling, Localization), By Application(Cancer, Infectious Diseases, Immunological Disorder, Cardiovascular Disease), By End-use(Biotechnology & Pharmaceutical Companies, Academic & Government Research Institutes, Others), By Region - Industry Forecast 2025-2032

Report ID: SQMIG35H2216 | Region: Global | Published Date: September, 2024
Pages: 157 | Tables: 61 | Figures: 75

MicroRNA Market Insights

MicroRNA Market size was valued at USD 1.35 Billion in 2023 and is poised to grow from USD 1.52 Billion in 2024 to USD 4.04 Billion by 2032, growing at a CAGR of 12.90% during the forecast period (2025-2032).

According to the estimates from the American Cancer Society, 609,360 deaths from cancer were registered in 2022 alone in the US, and over 1.9 million people were newly diagnosed with cancer. In addition, the pace at which microRNA diagnostics gained ground in clinical settings brought forward developments in precision medicine of cancer. As per the microRNA market analysis, the two key factors driving the growth of the market include growing prevalence of such diseases as cancer, heart disease, and other neurological conditions worldwide and rapid developments in genomic technologies. Furthermore, besides this, miRNAs have offered excellent noninvasive biomarkers for cancer. The reason behind this is that various secretions from numerous cells are present in various bodily fluids. Consequently, the functions of microRNA in gene regulation and disease pathways create a considerable market demand that drives the microRNA industry growth forward.

Since miRNAs play a crucial role in the post-transcriptional regulation of gene expression, they are rapidly being recognized as robust biomarkers of human disorders. Support for their utility as diagnostic and prognostic biomarkers in the form of blood is seen through their stability within serum and plasma. In addition, circulating miRNAs inside exosomes are serum biomarkers used to elucidate information regarding the immunological status in both healthy and pathological states. For instance, the concentration of microRNA-150 in the blood after lymphocyte activation sharply increases in vaccinated subjects. That lends credibility to the use of circulating microRNAs as potential indicators of immunologic status. Consequently, and expanding the business in general, prospects of using microRNA as a biomarker for a variety of diseases have an argument on its side.

US MicroRNA Market is poised to grow at a sustainable CAGR for the next forecast year.

MicroRNA Market Report Snapshots

License Type Top market research company in USA

File Type

$5,300

BUY NOW GET FREE SAMPLE

Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

MicroRNA Market size was valued at USD 1.20 billion in 2022 and is poised to grow from USD 1.35 billion in 2023 to USD 3.58 billion by 2031, growing at a CAGR of 12.90% during the forecast period (2024-2031).

The global microRNA industry is characterized by several competitors who are escalating their fight to capture market shares and gain a competitive edge. Research and development activities aimed at discovering new microRNA biomarkers, therapeutic targets, and diagnostic tools are driving the industry. Therefore, rivalry among market players is escalating too since such discoveries are promoting the development of new products and services based on microRNAs. Major players in the microRNA market include contract research firms, government and university research facilities, and biotechnology and pharmaceutical corporations. These organizations maintain the market via in-depth research, clinical studies, and commercialization of microRNA-based products. 'Thermo Fisher Scientific, Inc. (US) ', 'QIAGEN (Germany) ', 'NanoString Technologies, Inc. (US) ', 'Merck KGaA (Germany) ', 'Takara Bio, Inc. (Japan) ', 'BioGenex (US) ', 'GeneCopoeia, Inc. (US) ', 'New England Biolabs (US) ', 'Agilent Technologies, Inc. (US) ', 'Illumina, Inc. (US) ', 'Abcam plc (UK) ', 'Roche Holding AG (Switzerland) ', 'Arcturus Therapeutics Ltd. (US) ', 'Synthego Corporation (US) ', 'Bio-Techne Corporation (US) ', 'F. Hoffmann-La Roche Ltd. (Switzerland) ', 'Asuragen, Inc. (US) ', 'Cell Signaling Technology, Inc. (US) ', 'Molecular Cloud (China) ', 'Ribomed Biotechnologies, Inc. (US) ', 'Sirnaomics Inc. (US)'

Public and corporate funding in genomic research is opening new benefits in the microRNA industry. There is increased funding for conducting research in how microRNAs regulate gene functions and the development of illness. Such funding fast-tracks the creation of diagnostics and treatments through microRNA bases, and it facilitates innovation and cooperative research projects, thereby establishing their use in clinical settings.

Development of Combination Therapies: Major microRNA market trends include combination therapies. There is a growing trend wherein more emphasis is being laid down on combination therapy that consists of using a classical treatment in combination with a microRNA-based treatment. Researchers are looking into how they can better improve treatment outcomes and surmount drug resistance through the potential use of microRNAs in interfering with a multiplicity of pathways or enhancing the effectiveness of drugs already available on the market. As such, the trend tends to be more holistic where instead of targeting one pathway, the drugs and therapeutic approaches manage to achieve therapeutic gain through the exploitation of unique properties of microRNAs.

The microRNA market outlook highlighted that in 2023, the market was dominated by North America. This is so because growth in the region of microRNA is attributed to a number of factors, such as availability of significant population of major players in the area; some of which are Merck KGaA., NanoString Technologies, Inc., and Thermo Fisher Scientific, besides others whose expenditure on R&D has increased with them trying to come up with more advanced and innovative products. In 2023, the US accounted for the highest microRNA market share in North America. Some of the prominent players of the market with headquarters based in the US are Thermo Fisher Scientific, Merck KGaA., and QIAGEN. Distribution networks form the backbone of these players. The country enjoys simple access to miRNA services and products.

Feedback From Our Clients

"We have purchased recently a report from SkyQuest Technology, and we are happy to inform you that this report was so useful and practical for our team. Skyquest Team was very active and our queries were followed up completely.It was amazing. "

- Mr. Ali Zali, Commercial Director, ICIIC Iran.

MicroRNA Market Insights

MicroRNA Market Report Snapshots

Want to customize this report?

FAQs

What is the global market size of MicroRNA Market?

Who are the key vendors in the MicroRNA Market?

What is the key driver of MicroRNA Market?

What is the key market trend for MicroRNA Market?

Which region accounted for the largest share in MicroRNA Market?

Request Free Customization

Related Reports

Feedback From Our Clients

$5,300